Mankind Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 08-Aug-2025.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma's Board approved Q1 FY26 (quarter ended June 30, 2025) results, with consolidated revenue from operations rising about 24.5% year-on-year to ₹3,570.35 crore and standalone revenue growing nearly 19.5% to ₹2,541.36 crore. However, consolidated profit after tax fell to ₹438.32 crore (from ₹543.07 crore a year ago) and standalone PAT grew only about 8% to ₹412.76 crore, mainly dragged by higher finance costs and depreciation/amortisation following the ₹13,768 crore acquisition of Bharat Serums and Vaccines (BSV) completed in October 2024. The Board declared an interim dividend of ₹1 per share (100% on face value), with August 8, 2025 fixed as the record date. It also approved acquiring the Women Health Rx (branded generic) business from BSV via slump sale, raising up to ₹1,000 crore through commercial papers, and noted the resignation of the Chief Marketing Officer effective August 1, 2025. The auditors flagged an 'Emphasis of Matter' on ongoing income tax proceedings where disallowances of around ₹1,534 crore (standalone) and ₹1,547 crore (consolidated) have been raised, with the company contesting these in appeal.
Strong topline growth is positive, but near-term profitability is under pressure from integration costs of the large BSV acquisition; the dividend offers modest near-term support to shareholders, while the sizeable tax demand remains a key watchpoint despite management's view that it will not materially impact operations.